Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$112.19 USD
-1.50 (-1.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $112.16 -0.03 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 461 - 480 ( 520 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Updates from GIST study highlights BLU-285 Benefit across Genotype Spectrum
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Update Shows Broad and Deep Benefit with BLU-285 in SM
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Programs on Track, With Key Updates in Coming Months
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Update Shows Favorable PFS and Promising Path for Treatment-Naive HCC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Updated ORR; Additional Details at ESMO, ILCA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Data Releases on Tap, Next Up ?554 at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Continued Good Data for BLU-285 in Advanced GIST; Likely Speedy Registration Path
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Week Ahead: Focus Calls
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ASCO 2017 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D